Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Acelyrin
Biotech
Acelyrin to be absorbed into Alumis in all-stock merger
Eye-disease-focused Acelyrin will be absorbed into immune-mediated disease specialist Alumis as part of an all-stock merger.
James Waldron
Feb 7, 2025 5:35am
Affibody regains drug, says ex-ally unable to capitalize on data
Feb 3, 2025 5:18am
Acelyrin loses interest in izokibep, lays off 3rd of staff
Aug 13, 2024 4:00pm
Sanofi, Pfizer, Acelyrin and more—Chutes & Ladders
May 10, 2024 8:30am
Acelyrin's proof-of-concept TED data cement Amgen challenge
Mar 20, 2024 7:00am
Acelyrin rebounds with psoriatic arthritis victory
Mar 11, 2024 10:59am